Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma

被引：1

作者：

Abeykoon, Jithma P. ^{[1
]}

Vaxman, Luliana ^{[2
]}

Patel, Sanjay V. ^{[2
]}

Kumar, Shaji ^{[3
]}

Young, Kimberly S. ^{[2
]}

Ailawadhi, Sikander ^{[4
]}

Larsen, Jeremy T. ^{[5
]}

Gonsalves, Wilson I. ^{[6
]}

Kourelis, Taxiarchis ^{[1
]}

Leung, Nelson ^{[7
]}

Warsame, Rahma M. ^{[1
]}

Hobbs, Miriam A. ^{[1
]}

Fonder, Amie ^{[1
]}

Hwa, Yi L. ^{[1
]}

Bergsage, P. Leif ^{[8
]}

Lacy, Martha Q. ^{[6
]}

kumar, S. Vincent Raj ^{[1
]}

Gertz, Morie A. ^{[1
]}

Kapoor, Prashant ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN USA

[2] Mayo Clin, Rochester, NY USA

[3] Mayo Clin, Rochester, MN USA

[4] Mayo Clin, Div Hematol, Jacksonville, FL USA

[5] Mayo Clin, Div Hematol, Phoenix, AZ USA

[6] Mayo Sch Grad Med Educ, Div Hematol, Rochester, MN USA

[7] Mayo Clin Rochester, Div Hematol, Rochester, MN USA

[8] Mayo Clin, Div Hematol, Scottsdale, AZ USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-154183

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin
Menardais, B.
Soethoudt, M.
Espargilliere, D.
Mouriaux, F.
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (05): : 766 - 768
[22] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
Stocker, Nicolas
HEMATOLOGIE, 2020, 26 (02): : 99 - 100
[23] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
Condorelli, Annalisa
Garibaldi, Bruno
Gagliano, Caterina
Romano, Alessandra
Del Fabro, Vittorio
Parrinello, Nunziatina Laura
Longo, Antonio
Cosentino, Sebastiano
Di Raimondo, Francesco
Conticello, Concetta
ACTA HAEMATOLOGICA, 2021,
[24] Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
Neupane, Karun
Wahab, Ahsan
Masood, Adeel
Faraz, Tehniat
Bahram, Saman
Ehsan, Hamid
Hannan, Abdul
Anwer, Faiz
JOURNAL OF BLOOD MEDICINE, 2021, 12 : 529 - 550
[25] Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A SubStudy of the Cmrg-007 Trial
Louzada, Martha L.
Reece, Donna E.
McCurdy, Arleigh
Kotb, Rami
Othman, Ibraheem
Mian, Hira
Lin, Toni
Chu, Michael P.
White, Darrell
Parkin, Stephen
Gul, Engin
Khan, Aniba
Trudel, Suzanne
BLOOD, 2023, 142
[26] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
Hultcrantz, Malin
Orozco, Jennifer
Peterson, Tim J.
Derkach, Andriy
Hassoun, Hani
Korde, Neha
Lu, Sydney X.
Mailankody, Sham
Patel, Dhwani
Shah, Urvi A.
Tan, Carlyn
Maclachlan, Kylee H.
Chung, David J.
Landau, Heather J.
Shah, Gunjan L.
Lahoud, Oscar B.
Scordo, Michael
Landgren, Ola
Giralt, Sergio
Lesokhin, Alexander
BLOOD, 2021, 138
[27] Impact of baseline ocular conditions on belantamab mafodotin-related corneal events in relapsed/refractory multiple myeloma
Popat, Rakesh
Kazantzi, Aikaterini
Kleinman, David
Lichenstein, Carolyn
Paka, Prani
Salter, John
Byrne, Julie
Doherty, Allison
Esposti, Simona Degli
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 65 - 66
[28] Multiple Myeloma Belantamab Mafodotin opens up new Treatment Perspective
Sankawa, Yuri
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 427 - 428
[29] Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
Zhang, Yifei
Godara, Amandeep
Pan, Stacey
Toskic, Denis
Mann, Hashim
Sborov, Douglas
Comenzo, Raymond
Kansagra, Ankit
ANNALS OF HEMATOLOGY, 2022, 101 (09) : 2119 - 2121
[30] Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
Offidani, Massimo
Corvatta, Laura
More, Sonia
Olivieri, Attilio
DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2401 - 2415

← 1 2 3 4 5 →